The drug has been specifically recommended by the health technology assessment agency as an adjuvant treatment for adults with stage 1B to 3A ALK-positive non-small cell lung cancer (NSCLC).
Lung cancer is the third most common cancer in the UK and NSCLC accounts for approximately 90% of all cases. ALK-positive NSCLC is an aggressive form of the disease and is common in younger patients with little or no smoking history…
